+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Norovirus Vaccines in pipeline forecast set to grow to $158m by 2025” says new Visiongain report

19 December 2019
Pharma

Visiongain has launched a new pharma report Global Norovirus Vaccines in Pipeline Forecast 2020-2030: Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics.

Norovirus has become the leading cause of medically attended acute gastroenteritis and is a common cause of outbreaks worldwide. There is no licensed norovirus vaccine yet, but there are promising candidate vaccines in the pipeline. This burden affects children under 5 years of age and people in developing countries overwhelmingly.

The lead analyst of the report commented "Despite external stimuli, such as a major donor, developed global markets are likely to provide the initial economic support for the production of norovirus vaccines for private industry. Early phase trials among adults in high-income settings have been conducted to date, leaving a need for a paediatric development plan."

Leading companies featured in the report include Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever